Bausch & Lomb (FRA:S2L) Total Liabilities : €6,039 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Total Liabilities?

Bausch & Lomb's Total Liabilities for the quarter that ended in Mar. 2024 was €6,039 Mil.

Bausch & Lomb's quarterly Total Liabilities increased from Sep. 2023 (€5,795.35 Mil) to Dec. 2023 (€5,980.67 Mil) and increased from Dec. 2023 (€5,980.67 Mil) to Mar. 2024 (€6,038.88 Mil).

Bausch & Lomb's annual Total Liabilities increased from Dec. 2021 (€1,257.59 Mil) to Dec. 2022 (€3,816.59 Mil) and increased from Dec. 2022 (€3,816.59 Mil) to Dec. 2023 (€5,980.67 Mil).

Bausch & Lomb Total Liabilities Historical Data

The historical data trend for Bausch & Lomb's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Total Liabilities Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,292.40

1,050.52

1,257.59

3,816.59

5,980.67

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial												3,845.28	3,955.06	5,795.35	5,980.67	6,038.88

Bausch & Lomb Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bausch & Lomb's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1447.943	+	(4155.844	+	364.049
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	12.838	+	0)
	=	5,981

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	12326.314	-	6345.64
	=	5,981

Bausch & Lomb's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1487.64	+	(4189.68	+	348.68
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	12.88	+	0)
	=	6,039

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	12229.56	-	6190.68
	=	6,039

Bausch & Lomb Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (FRA:S2L) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (FRA:S2L) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BLCO:USA BLCO:Canada

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Bausch & Lomb (FRA:S2L) Headlines

No Headlines